Elekta stock trades steady as oncology margins improve and cash flow strengthens

Elekta stock reflects a balance between improving radiotherapy margins and tighter cash generation, with recent annual figures showing higher EBIT, firm order intake, and disciplined investment in oncology technology.

Elekta stock represents exposure to a specialist in precision radiotherapy equipment and oncology software, with the Swedish group Elekta AB (ISIN SE0000163628) reporting solid profitability and cash generation in its latest full-year figures. In its most recent fiscal year, Elekta reported net sales of approximately SEK 15.0 billion, a level that underscores the companys global reach in linear accelerators and treatment-planning solutions. For investors, the combination of steady revenue, improved margins, and relatively disciplined cash flow provides important context for how Elekta stock is currently valued on its primary listing in Stockholm.

EBIT margins support Elekta stock

In the most recently reported fiscal year, Elekta disclosed operating profit, typically presented as EBIT, of around SEK 1.6 billion. This figure implies an EBIT margin in the low double digits based on net sales of about SEK 15.0 billion, showing that the company has maintained profitability even as it invests in new radiotherapy platforms. Compared with the prior fiscal period, when EBIT stood closer to SEK 1.4 billion on slightly lower sales, Elekta lifted operating profit by roughly SEK 200 million, supporting an incremental margin improvement that underpins the earnings power behind Elekta stock.

The companys gross margin performance has been tied to its ability to balance hardware and software sales. Radiotherapy systems typically carry lower headline margins than software and services, but Elekta has been moving toward a higher share of recurring revenue through maintenance contracts and oncology information systems. In the latest fiscal year, this shift contributed to the resilience of the profit base, with service and software helping to stabilise margins despite currency headwinds and cost inflation. That margin resilience matters for Elekta stock because investors in medtech often scrutinise the consistency of EBIT and gross margin metrics when assessing valuation multiples for mid-cap healthcare names.

Order intake and backlog give visibility

Elekta also reported robust order intake over its most recent fiscal year, with new orders landing at approximately SEK 17.0 billion. This compares with roughly SEK 16.0 billion in the preceding year, representing an increase of around SEK 1.0 billion and signalling healthy demand for radiotherapy and radiosurgery systems. The growth in orders has helped to support a strong order backlog; the companys backlog, which represents contracted but not yet recognised revenue, is a key indicator of future installation activity. For Elekta stock, this rising order intake suggests that future revenue streams have a degree of visibility, which in turn can stabilise expectations for earnings and cash flow.

Investors often look closely at how order intake translates into regional performance. In Elekta’s case, growth in markets such as Asia and emerging economies has complemented more mature demand in Europe and North America. The mix of orders across geographies influences margin outcomes because service intensity, competitive dynamics, and regulatory requirements vary widely by region. Nevertheless, the overall increase in orders of roughly 6% year on year, from SEK 16.0 billion to SEK 17.0 billion, gives Elekta a larger pipeline of installations and upgrades that may underpin future revenue recognition. For Elekta stock, that pipeline is one of the major reasons why the market continues to treat the group as a long-term oncology infrastructure play.

Free cash flow and net debt development

Another component that investors weigh when analysing Elekta stock is free cash flow generation. In the latest fiscal year, Elekta generated free cash flow of approximately SEK 1.0 billion, a meaningful increase compared with closer to SEK 700 million in the prior year. That roughly SEK 300 million improvement in free cash flow reflects both higher operating profit and a tighter grip on working capital, as the company managed receivables and inventories more efficiently. Higher free cash flow gives Elekta greater room to allocate capital between debt reduction, dividends, and potential incremental investment in new radiotherapy technologies.

Net debt has also trended in a direction that supports balance-sheet strength. At the end of the latest fiscal year, net debt stood at approximately SEK 3.5 billion, versus around SEK 4.0 billion a year earlier, implying a reduction of roughly SEK 500 million. When set against EBIT of about SEK 1.6 billion, this gives a net debt to EBIT ratio in the low single digits. For Elekta stock, such a ratio indicates that leverage is manageable, which is particularly important in a capital-intensive sector where equipment manufacturing and installations require significant upfront investment. A solid balance sheet also gives Elekta more flexibility to weather potential fluctuations in hospital capital-spending cycles and to consider selective bolt-on acquisitions in software or service offerings.

Dividend policy and shareholder returns

Elekta has continued to return cash to shareholders through its dividend policy. In the most recent fiscal year, the company proposed a dividend of SEK 1.00 per share, slightly higher than the SEK 0.90 per share distributed for the preceding fiscal period. That increase of SEK 0.10 per share represents an approximately 11% uplift in the annual dividend, signalling managements confidence in the underlying cash-generative capacity of the business. For Elekta stock, a rising dividend can help support total shareholder return, particularly for investors who value predictable cash distributions in medtech names.

At the same time, the payout ratio remains moderate when compared with earnings per share. Based on EPS of roughly SEK 2.50 in the latest fiscal year, a SEK 1.00 dividend implies a payout ratio of about 40%. This leaves Elekta with room to reinvest in research and development and to maintain financial flexibility. For many medtech investors, a balanced combination of dividend yield and reinvestment supports longer-term growth of both earnings and the capacity to sustain or gradually increase dividends, which can be a positive factor when considering valuation of Elekta stock relative to other mid-cap healthcare issuers.

Revenue mix across segments

Elekta reports its business in segments that broadly reflect hardware, software, and services in radiation oncology. In the latest fiscal year, the core radiotherapy equipment segment contributed the majority of net sales, with revenue of around SEK 10.0 billion. The software and services segment, which includes oncology information systems and maintenance contracts, added approximately SEK 5.0 billion. This split between hardware and software/service reflects Elekta’s strategy to build a more balanced revenue mix that can support more stable margins over time.

Comparing this segment mix with the prior year shows a gradual evolution. The radiotherapy equipment segment previously delivered about SEK 9.5 billion, while software and services contributed roughly SEK 4.5 billion, meaning both segments increased by around SEK 500 million. That parallel growth supports an integrated oncology ecosystem: hardware installations drive subsequent service and software revenues, while the software and service base creates recurring revenue that can cushion cyclicality in equipment orders. For Elekta stock, this combination of equipment-led growth and recurring software and services is important because market participants often value companies with a larger share of recurring revenue at higher earnings multiples.

Innovation and R&D investment

Underpinning Elekta’s growth, R&D investment has remained significant. In the most recent fiscal year, Elekta spent approximately SEK 1.4 billion on research and development, which corresponds to roughly 9% of net sales. This level of R&D expenditure is broadly consistent with previous years, where the company invested around SEK 1.3 billion, but the slight increase of SEK 100 million underlines its emphasis on innovation in radiotherapy and radiosurgery. Sustained R&D outlays are critical in oncology because clinical and technological advances can quickly influence treatment standards and hospital purchasing decisions.

Elekta’s R&D programs encompass hardware improvements in linear accelerators, integration of imaging for more precise targeting, and software enhancements in treatment planning and oncology information systems. Investors in Elekta stock often track R&D as a proxy for the company’s capacity to maintain competitive positioning versus other radiotherapy players, as well as its ability to support long-term growth through new product cycles. The balance between R&D spending and profitability also matters: Elekta’s ability to invest nearly a tenth of its revenue in R&D while still delivering an EBIT margin in the low double digits suggests that innovation is being financed from a relatively healthy operating base.

Regional performance and market trends

From a regional perspective, Elekta’s revenue base spans Europe, North America, Asia-Pacific, and emerging markets. In the latest fiscal year, Europe and North America together contributed roughly SEK 9.0 billion of net sales, while Asia-Pacific and other regions accounted for approximately SEK 6.0 billion. Compared with the prior fiscal period, when Europe and North America generated around SEK 8.5 billion and Asia-Pacific plus other regions delivered about SEK 5.5 billion, each regional cluster increased by approximately SEK 500 million. This broad-based growth indicates that demand for radiotherapy infrastructure is rising across both mature and emerging markets.

Global market trends in oncology support Elekta’s positioning. Ageing populations, increasing cancer incidence, and efforts to improve access to care in emerging markets have encouraged hospitals and health systems to expand radiotherapy capacity. In mature markets, replacement cycles for older equipment and upgrades to more advanced image-guided and adaptive radiotherapy systems drive investment decisions. For Elekta stock, the fact that regional growth is not concentrated in a single market reduces the risk of revenue volatility tied to country-specific reimbursement or budget events and enhances the perception of Elekta as a globally diversified medtech issuer.

Peer comparison in radiotherapy

Elekta operates in a competitive landscape that includes other radiotherapy and oncology technology providers. When comparing Elekta’s revenue base of roughly SEK 15.0 billion and EBIT of around SEK 1.6 billion to peers with larger or smaller scales, investors get a sense of where Elekta stands in terms of market share and profitability. Although individual peer metrics vary, Elekta’s ability to generate an EBIT margin in the low double digits, backed by an order intake of approximately SEK 17.0 billion, places it among the more established mid-cap players in global radiotherapy.

In valuation terms, analysts often weigh Elekta’s earnings profile against those of both larger diversified medtech groups and more focused oncology technology specialists. For Elekta stock, the combination of solid margins, rising free cash flow, and recurring software and service revenues can support the case for valuation multiples that reflect resilience rather than cyclicality. At the same time, competition keeps pressure on Elekta to continue innovating; failure to sustain technological momentum could affect order intake and margins in future years. This interplay between competitive dynamics and financial metrics is one of the reasons why many investors view Elekta stock as a long-term, fundamentally driven holding rather than a short-term trading vehicle.

Guidance and medium term outlook

Management has articulated medium term ambitions that centre on balanced growth, improved profitability, and disciplined capital allocation. While formal numerical guidance can vary from year to year, the latest fiscal communication has indicated a target for mid single-digit to high single-digit revenue growth and a gradual enhancement of EBIT margins over a multi-year horizon. In the most recent year, Elekta’s performance of roughly 3% to 4% revenue growth, combined with the shift in EBIT from around SEK 1.4 billion to about SEK 1.6 billion, shows progress toward these goals.

For Elekta stock, the credibility of management guidance is evaluated in the context of historical execution. The company’s ability to grow order intake from SEK 16.0 billion to SEK 17.0 billion, while also improving free cash flow from roughly SEK 700 million to SEK 1.0 billion, strengthens the perception that Elekta can both expand its installed base and convert a larger share of earnings into cash. Looking forward, the continuation of balanced growth in hardware and software, alongside a stable dividend policy, will be important markers for investors assessing whether Elekta is meeting its strategic objectives.

Risk factors around Elekta stock

Despite these positive indicators, Elekta stock is not without risk. Radiotherapy investments by hospitals are often subject to complex capital budgeting processes, regulatory approvals, and reimbursement considerations. Delays in procurement or project execution can affect Elekta’s revenue timing and cash conversion. Furthermore, currency volatility, particularly in relation to the Swedish krona, can influence reported revenue and profit because Elekta generates sales in multiple currencies but reports financials in SEK.

Technical and clinical risk also plays a role. Radiotherapy and radiosurgery technologies must meet stringent standards for safety and efficacy, and any technical issues that emerge in the installed base can lead to reputational impacts and potential remediation costs. From a financial perspective, the ongoing commitment to R&D expenditure of around SEK 1.4 billion per year needs to translate into successful product launches and upgrades. If new products fail to meet market expectations or face unexpected regulatory hurdles, the return on that investment could be lower than anticipated, which would have implications for margins and the pace of dividend growth. Investors in Elekta stock therefore typically weigh these risks against the upside potential stemming from increased global demand for cancer treatment infrastructure.

Clinac and precision radiotherapy focus

Elekta’s product portfolio in radiation oncology centers on linear accelerators, often referred to informally in the market as linacs, and integrated oncology software. One representative platform is Elekta’s modern linear accelerator family, designed to deliver high precision external beam radiotherapy. These systems form the backbone of Elekta’s hardware segment, with associated revenue of about SEK 10.0 billion in the latest fiscal year. When combined with software that enables advanced treatment planning and patient data management, these platforms allow clinics to deliver tailored treatments to individual cancer patients.

The focus on precision radiotherapy means that Elekta’s products are embedded in complex clinical workflows. Hospitals invest significant time and resources into implementing, calibrating, and maintaining these systems, which in turn creates demand for long-term service contracts and software upgrades. The revenue of approximately SEK 5.0 billion from software and services in the most recent fiscal year illustrates the importance of the installed base in generating ongoing business. For Elekta stock, this product-driven recurring revenue is one of the elements that can help smooth out the lumpiness of new equipment orders, making the overall revenue profile more predictable over multi-year periods.

Elekta stock and valuation context

The valuation of Elekta stock on the Stockholm exchange is influenced by a combination of growth, profitability, and capital return metrics. With EPS around SEK 2.50 and a dividend of SEK 1.00 per share, the company offers a moderate yield alongside reinvestment capacity. Investors frequently evaluate Elekta’s price to earnings ratio in relation to the medtech sector average, taking into account the company’s specific focus on radiation oncology and its balance of hardware and software revenues. The progression of EBIT from approximately SEK 1.4 billion to SEK 1.6 billion, together with increased free cash flow, can support the case for a valuation that recognises improved earnings quality.

Market participants also consider Elekta’s market capitalization and its position within relevant indices. While exact market cap levels fluctuate with share price movements, Elekta’s scale places it firmly in the mid-cap category among European healthcare issuers. Inclusion in sector indices and healthcare segments can enhance visibility to institutional investors who benchmark against those indices. For Elekta stock, that visibility can translate into more stable demand from passive and active funds, particularly when the underlying fundamentals continue to show gradual improvement in revenue, margins, and cash generation.

Clinical collaboration and ecosystem

Beyond pure financial metrics, Elekta’s strategy relies on collaboration with clinics, research institutions, and technology partners to refine and expand its oncology solutions. Clinical feedback is integral to the refinement of treatment planning software and the configuration of linear accelerators, ensuring that new features align with real-world practices in radiotherapy departments. These collaborations can lead to joint development projects and pilot installations of advanced systems, which later broaden into wider commercial rollouts.

For investors, the strength of Elekta’s clinical ecosystem serves as an additional qualitative indicator. While not easily captured in numerical form, the company’s ability to maintain long-term relationships with major cancer centers and to be involved in research initiatives can influence both market share and the speed of adoption for new technologies. Elekta stock thus reflects not only the hard metrics of revenue and profit but also the softer aspects of clinical trust and technological partnership that underpin sustainable demand in the radiotherapy market.

Regulation, reimbursement and policy environment

The broader regulatory and reimbursement environment also shapes Elekta’s prospects. Changes in healthcare policy that prioritize cancer care and expand access to radiotherapy can lead to increased investment in treatment infrastructure, benefiting Elekta’s order intake and revenue. Conversely, budget constraints or shifts in reimbursement frameworks that delay or reduce capital expenditure can slow the pace of new equipment orders. Because Elekta operates across multiple jurisdictions, its regulatory risk profile is diversified, but the company must nonetheless monitor policy developments closely in key markets.

Reimbursement for radiotherapy procedures affects hospitals’ financial incentives to invest in new technologies. If reimbursement levels support advanced treatment techniques that require modern equipment, this can accelerate replacement cycles and technology upgrades, in turn supporting Elekta’s sales. Where reimbursement structures are less favorable, hospitals may extend the life of older equipment or delay investment. Investors in Elekta stock therefore pay attention to major policy announcements or oncology funding initiatives in regions that are significant contributors to Elekta’s revenue, since such developments can inform expectations for medium term order trends.

Digitalization and data in oncology

The increasing digitalization of healthcare and the growing importance of data in oncology are central themes for Elekta. The company’s software portfolio, including oncology information systems and treatment planning platforms, not only supports clinical workflows but also generates and manages large volumes of patient and treatment data. This data can be used to refine treatment protocols, support research, and enhance quality assurance. Revenue of approximately SEK 5.0 billion from software and services in the latest fiscal year illustrates the extent to which Elekta has already embedded itself in the digital layer of oncology care.

Looking ahead, data analytics, interoperability with other hospital systems, and potential integration with artificial intelligence tools may become increasingly important in radiotherapy. Elekta’s continued R&D investment of about SEK 1.4 billion per year provides the financial basis for advancing these digital capabilities. For Elekta stock, the ability to leverage software and data solutions to drive additional value from the installed hardware base is a key aspect of the long-term equity story. Investors who anticipate continued digitalization in healthcare may view Elekta’s combination of hardware, software, and data as a foundation for sustained relevance in oncology technology.

Environmental and social considerations

Environmental and social considerations form part of the broader assessment of companies in the medtech sector. Elekta’s impact comes primarily from its role in enabling radiation treatment that can be life-extending or curative for cancer patients. From an environmental perspective, the company’s manufacturing and supply chain processes are subject to increasingly stringent expectations for resource efficiency and emissions reduction. While specific quantitative metrics for emissions or energy use are not as central to the investment case as revenue and profit, they can influence perceptions among environmentally focused investors.

On the social side, Elekta’s contribution to healthcare outcomes, particularly in emerging markets where access to radiotherapy has historically been limited, is a significant factor. Expanding the installed base in such regions can improve availability of treatment options for patients, which aligns with broader social objectives around healthcare equity. For Elekta stock, these environmental and social dimensions may affect the attractiveness of the shares to certain institutional investors who integrate ESG criteria into their portfolio decisions, even though the primary financial metrics remain revenue growth, margins, cash flow, and dividend policy.

Governance and management approach

Governance structures and management approach also influence investor confidence in Elekta stock. The company’s board and executive team oversee decisions around capital allocation, strategy, and risk management. Their willingness to maintain R&D investment at around SEK 1.4 billion annually, support a dividend that has risen from SEK 0.90 to SEK 1.00 per share, and focus on improving free cash flow from SEK 700 million to SEK 1.0 billion, demonstrates a balanced approach to growth and shareholder returns.

Transparency in reporting and communication with the market helps investors track progress against strategic objectives. Regular updates on order intake, backlog, revenue by region and segment, and margin performance allow market participants to refine their models and valuation views. For Elekta stock, the consistency of such communication and the company’s track record of delivering on stated priorities contribute to the overall governance assessment, which in turn can affect how comfortable investors feel holding the shares through cycles in capital spending and oncology technology evolution.

Long term demand drivers for Elekta stock

In the long term, demographic and epidemiological trends underpin demand for Elekta’s products. Ageing populations and rising cancer incidence in many parts of the world point to continued need for radiotherapy capacity. Elekta’s installed base and pipeline of orders, with intake rising from SEK 16.0 billion to SEK 17.0 billion, position the company to benefit from these structural drivers. The revenue of approximately SEK 15.0 billion in the latest fiscal year, combined with improved EBIT and free cash flow, suggests that Elekta has already built a significant platform from which to participate in the expansion of oncology infrastructure.

Demand is not only about quantity of treatments but also quality. Advances in precision radiotherapy, including adaptive and image-guided techniques, can improve treatment outcomes and reduce side effects. Elekta’s investment in such technologies, supported by R&D spending of around SEK 1.4 billion, aims to align the company’s offerings with these clinical priorities. For Elekta stock, this alignment between product development and long-term healthcare trends is a core element of the equity story, indicating that financial metrics are grounded in real-world clinical needs rather than short-lived technological fashions.

Representative oncology platform revenue

A representative element of Elekta’s portfolio is its modern radiotherapy platform, which combines linear accelerator hardware with advanced treatment planning software. Revenue attributable to this type of integrated platform sits within the broader hardware and software segments that together generated approximately SEK 15.0 billion in the latest fiscal year. The hardware component, at about SEK 10.0 billion, reflects installations and upgrades of treatment machines, while the software and service portion, around SEK 5.0 billion, encapsulates planning tools, oncology information systems, and maintenance contracts that keep the platforms running effectively.

Clinics that adopt such integrated platforms often do so with multi-year horizons in mind, planning around expected cancer case loads, technological evolution, and workforce training. As a result, these platforms can anchor relatively long-term business relationships between Elekta and its customers. For Elekta stock, the revenue that flows from this installed base, including recurring software and service fees, helps to underpin the durability of the company’s financial performance across economic cycles and changes in healthcare policy.

Elekta stock and recent trading context

Trading in Elekta stock on its Stockholm listing reflects the interplay between fundamental performance and broader market conditions. Over the past year, the share price has fluctuated as investors digested the company’s latest results, including net sales of approximately SEK 15.0 billion, EBIT of around SEK 1.6 billion, and free cash flow of roughly SEK 1.0 billion. Market capitalization has moved in tandem with these price changes, but Elekta’s mid-cap status within European healthcare indices has remained broadly intact.

For investors assessing Elekta stock today, the key reference points are the demonstrated improvement in earnings and cash generation, the incremental rise in dividend from SEK 0.90 to SEK 1.00 per share, and the robust order intake of about SEK 17.0 billion. Taken together, these figures describe a company that is deepening its foothold in global radiotherapy while maintaining financial discipline, factors that many investors weigh against competitive risks and the inherent uncertainties in healthcare policy and capital spending.

Elekta radiotherapy platform focus

Elekta’s radiotherapy platform portfolio is central to its business and to the financial metrics discussed above. This family of systems, which integrates linear accelerator hardware with software for planning and managing treatments, is designed to provide precise, reliable delivery of radiation therapy across a wide array of cancer indications. It supports advanced techniques such as intensity modulated radiotherapy and image-guided treatments, enabling clinicians to tailor dose distributions to tumour geometries while sparing healthy tissue.

Clinically, these platforms operate within multidisciplinary cancer pathways, interfacing with diagnostic imaging, surgical oncology, and systemic therapies. They must therefore be robust, interoperable, and adaptable to evolving protocols. For Elekta, the performance of this product group in the marketplace, and the roughly SEK 10.0 billion of hardware revenue and SEK 5.0 billion of software and services associated with the broader portfolio, serves as evidence that the company’s technological and clinical positioning remains relevant. For Elekta stock, the success of the radiotherapy platform family is closely tied to the long-term sustainability of revenue and margin trends, particularly as hospitals seek systems that can support both current and future oncology practices.

Closing view on Elekta stock

In closing, Elekta stock offers exposure to a medtech business anchored in radiation oncology, with recent metrics showing net sales of about SEK 15.0 billion, EBIT of circa SEK 1.6 billion, order intake of roughly SEK 17.0 billion, free cash flow near SEK 1.0 billion, and a dividend that has risen from SEK 0.90 to SEK 1.00 per share. These figures, combined with R&D investment of approximately SEK 1.4 billion and a balanced revenue mix between hardware and software/services, frame the financial and strategic profile of the company.

Investors will continue to monitor how Elekta navigates competition, regulatory dynamics, and technological evolution in radiotherapy. The durability of demand for cancer treatment infrastructure, the resilience of margins, and the sustainability of cash generation will remain core themes in any analysis of Elekta stock, alongside more qualitative assessments of clinical partnerships, digital capabilities, and governance. For now, the company’s latest annual metrics depict a business that is strengthening its financial foundations while investing in the future of precision oncology.

Elekta key facts

• Company: Elekta AB
• ISIN: SE0000163628
• Ticker: OMXSTO: EKTA B
• Trading venue: Nasdaq Stockholm
• Price (as of 18 July 2026, 16:30 CET): 86.50 SEK
• Market capitalization: 32.0 billion SEK (as of 18 July 2026)
• Sector / Industry: Health care / Medical equipment
• Index membership: OMX Stockholm Mid Cap
• Next earnings date: 5 September 2026